PHARMAFRONTIERS TO PRESENT TOVAXIN RESEARCH AT UPCOMING MS MEETING

PharmaFrontiers announced that their research of their Phase I/II clinical trials of Tovaxin, a novel T cell therapeutic vaccine for multiple sclerosis, has been accepted for presentation at the 21st Congress of the European Committee/10th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis, to be held this fall in Thessaloniki, Greece.

The interim trial results have indicated that the treatment appears safe and well tolerated. Tovaxin is a trivalent formulation of attenuated myelin-peptide reactive T cells (MRTCs), which are derived from peripheral blood and produced ex vivo as myelin basic protein, proteolipid protein, and myelin oligodendrocyte glycoprotein reactive T cells.

In addition to the safety and tolerance indications, the study concluded that MRTCs in patients with MS can be depleted by Tovaxin treatment.